{"slug":"clinicalintelpulse-theaslangroupllc-com-api-clinical-deal-si-82610f","title":"Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial co","host":"clinicalintelpulse.theaslangroupllc.com","method":"GET","resource":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal-lite","category":"other","description":"Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likel","price_listed":0.25,"price_asked":0.25,"state":"answering","state_label":"Answering","checks_7d":1,"answered_7d":1,"latency_ms_median":286,"reported_calls_30d":1,"reported_payers_30d":1,"networks":["algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","eip155:137","eip155:143","eip155:196","eip155:42161","eip155:480","eip155:56","eip155:8453","eip155:999","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","xrpl:0"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"method":"GET","queryParams":{"condition":"Disease area — e.g. \"Obesity\" | \"Cardiovascular\" | \"Oncology\" | \"Rare Neurological\" | \"Autoimmune\"","stage":"phase2 | phase3 | both (default: both)"},"type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"properties":{"condition":{"type":"string"},"stage":{"type":"string"}},"type":"object"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"errors":{"additionalProperties":{"properties":{"description":{"type":"string"},"example":{"type":"object"}},"required":["description"],"type":"object"},"description":"Documented error responses, keyed by HTTP status code","type":"object"},"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-10-18","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.25,"price_match":true,"latency_ms":286,"error":null}],"description_full":"Deterministic preview of biotech M&A deal-signal candidates — Phase 2/3 trial counts and the industry-sponsored asset list straight off ClinicalTrials.gov, no LLM synthesis. For agents with small per-call budgets; upgrade to deal-signal for acquisition rationale, deal comps with dollar values, likely acquirers and timing signals.","last_updated":"2026-10-16T02:44:10.915Z","schemes":["exact"]}